## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Applicant:

Eduardo N. MITRANI

Serial No.:

10/009,520

Filed:

May 3, 2002

For:

METHOD OF INDUCING ANGIOGENESIS

BY MICRO-ORGANS

Examiner:

ANGELL, JON E

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 JUL 0 6 2006 BY

Group Art Unit: 1635

Attorney

*\$* \$\text{\$\}\$}}}}\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\exititt{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\

Docket: 01/22858

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: July 3, 2006

IUL 0 6 2006

Attorney Docket Number

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Pate thand Trademark Office; U.S. DEPARTMENT OF COMMERCE ction of internation unless it contains a valid OMB control number.

U.S.Fa
Under the Paperwork Reduction Act of 1995, no persons are required to responding collection of in

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known
Application Number 10/009,520

Filing Date May 3, 2002

First Named Inventor Eduardo N. MITRANI
Art Unit 1635

Examiner Name ANGELL, JON E

01/22858

			U.S. PATENT I		
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
•	,		11.00.1000		
	l	US-5,266,480	11-30-1992	Naughton et al.	
	2	US-3,850,752	11-26-1974	Schuurs et al.	
	3	US-3,850,578	11-26-1974	McConnell et al.	
	4	US-4,498,778	02-12-1985	White	
	5	US-5,888,720	03-30-1999	Mitrani	
	6	US-5,753,612	05-19-1998	Mitrani	
-			_		
					-
					•

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY		of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	7	PCT WO 98/25964	06-18-1998	Badylak e	et al.		П
	8	EP 0357958	05-26-1993	Steinbach	et al.		
	9	PCT WO 01/07098	01-1-2001	Mitrani	ni		П
	10	PCT WO 00/53795	09-14-2000	Katz et al.			$\Box$
	11	PCT WO 01/23541	05-5-2001	Fodor et al.			T
	12	PCT WO 97/15655	01-1-1997	Sittinger et al.			T
	13	JP 11-76399	03-23-1999	Imai et al.			П
							$\perp$
	<del>                                     </del>			-			$\vdash$
Examiner Signature			•		Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it or

	Sul	estitute for form 1449A/PTO			e if Knowr				
ATT===			Application Number 10/009						
SUPPL		TAL INFORMATION D	Filing Date May 3, 2		2002				
	STA	TEMENT BY APPLICA	First Named Inventor	entor Eduardo N. MITRA					
		(use as many sheets as necessary)	Group Art Unit	1635					
				Examiner Name	ANGELL, JON E				
Sheet	2	of	3	Attorney Docket Number	01/22858				
<del> </del>		OTHER PRIOR ART – N	ON PATENT LITER	ATURE DOCUMENTS	S				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	14	Soyer et al. "Extracorporeal Assist of Anhepatic Animals With Liver Slice Perfusion", The American Journal of Surgery, P.21-26, 1973.							
	15	Rubanyi "The Future of Human 22(3): 113-142, 2001.	Rubanyi "The Future of Human Gene Therapy", Molecular Aspects of Medicine,						
	16	Parrish et al. "Minireview: Precision-Cut Tissue Slices: Applications in Pharmacology and Toxicology", Life Sciences, 57(21): 1887-1901, 1995.							
100	17	Villeval et al. "Retrovirus-Mediated Transfer of the Erythroprotein Gene in Hematopoietoic Cells Improves the Erythrocyte Phenotype in Murine β-Thalassemia", Blood, 84(3): 928-933, 1994.							
v -	18	Descamps et al. "Organoids Direct Systematic Expression of Erythropoietin in Mice", Gene Therapy, 2: 411-417, 1995.							
1100	19	Palù et al. "In Pursuit of New Developments for Gene Therapy of Human Diseases", J. Biotechnology, 68: 1-13, 1999.							
	20	Romano et al. "Gene Transfer Technology in Therapy: Current Applications and Future Goals", Stem Cell, 17: 191-202, 1999.							
	21	Kappel et al. "Regulating Gene Expression in Transgenic Animals", Current Opinion in Biology, 3: 548-553, 1992.							
	22	Mullins et al. "Transgenesis in Nonmurine Species", Hypertension, 22(4): 630-633, 1993.							
·	23	Mullins et al. "Transgenesis in the 1557-1560, 1996.	ne Rat and Larger Man	nmals", J. Clin. Invest.,	97(7):				
	24	Houdebine "Production of Pharm Biotechnology, 34: 269-287, 199	naceutical Proteins Fro	m Transgenic Animals	", J.				
	25	Wall "Transgenic Livestock: Pro 45: 57-68, 1996.		r the Future", Thenoger	nology,				
	26	Sigmund "Viewpoint: Are Studie Arterioscler. Thromb. Vasc. Bio	es in Genetically Altere	ed Mice Out of Control	?",				
	27	Niemann "Transgenic Farm Anii 73-75, 1998.	mals Get Off the Groun	nd", Transgenic Resear					
	28	Crystal "Transfer of Genes to Hu Science, 270: 404-410, 1995.	ımans: Early Lessons a	and Obstacles to Succes	ss",	-			
	29	Verma et al. "Gene Therapy - Pro 242, 1997.	omises, Problems and	Prospects", Nature, 389	239-				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Older the Paperw	YOR REGUETION	1 Act of 1993, no persons are required to respond to a co	meetion of information un						
	Su	bstitute for form 1449A/PTO	Complete if Known Application Number 10/009,520						
SUPPL		TAL INFORMATION DISC	Filing Date May 3, 2002  First Named Inventor Eduardo N. MI  Group Art Unit 1635						
	STA	TEMENT BY APPLICANT			N. MITRANI				
		(use as many sheets as necessary)							
				Examiner Name	ANGEL	L, JON E			
Sheet	3	of	3	Attorney Docket Number	01/22858				
		OTHER PRIOR ART – NON							
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	30	Deonarain "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery", Exp. Opin. Ther. Patents, 8(1): 53-69, 1998.							
	31	Miller et al. "Targeted Vectors for Gene Therapy", FASEB J., 9: 190-199, 1995.							
-	32	Eck et al. "Gene-Based Therapy", in: Goodman & Gilman's 'The Pharmacological Basis of Therapeutics', 9/E, Chap.5: 77-101, 1997.							
	33	Ledley "Pharmaceutical Approach to Somatic Gene Therapy", Pharm. Res., 13(11): 1595-1614, 1996.							
	34	Saadi et al. "Immunology of Xenotransplantation", Life Sciences, 62(5): 365-387, 1998.							
	35	Inverardi et al. "Cell Transplantation", in: 'Transplantation Biology: Cellular and Molecular Aspects', Raven Pub., Chap. 56, 1996.							
	36	Philpott et al. "Rat Hair Follicle Growth In Vivo", Br. J. Derm., 127: 600-607, 1992.							
	37	Lingna "Skin Toxicity Determined In Vitro by Three-Dimensional, Native-State Histoculture", Proc. Natl. Acad. Sci. USA, 88: 1908-1912, 1991.							
• •	38	Cameron "Recent Advances in Transgenic Technology", Molecular Biotechnology, 7: 253-265, 1997.							
	39	Eto et al. "Purification and Charcterization of Erythroid Differntiation Factor (EDF) Isolated From Human Leukemia Cell Line THP-1", Biochemical and Biophysical Research Communications, 142(3): 1095-1103, 1987.							
	40	Chesnokova et al. "The Thymic Factor Tactivin Prevents ACTH From Stimulating Steroldogenesis by Mouse Adrenal Cells", Institute of Cytology and Genetics, USSR Academy of Science, 1990.							

Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.